Soligenix, incorporation
SNGX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
SNGX 近期報酬表現
-5.80%
Soligenix, incorporation
-0.10%
同產業平均
-1.57%
S&P500
與 SNGX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
CMND | Clearmind medicine inc | - | 2 分 | 4 分 | - | 1 分 | |
LXEO | Lexeo therapeutics inc | - | 2 分 | 4 分 | 3 分 | 1 分 | |
CDT | Conduit pharmaceuticals inc | - | 2 分 | 4 分 | - | 1 分 | |
NEXI | Neximmune inc | 2 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
CPHI | China pharma holdings, inc. | - | 2 分 | 4 分 | - | 1 分 |
- CMND Clearmind medicine inc價值 -趨勢 2 分波段 4 分籌碼 -股利 1 分查看更多
SNGX 公司資訊
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.